Regular reports of biotech and medtech companies failing to disclose corporate and clinical data and breaching of clinical trials standards are of cause for concern.

In an interview with Ausbiz, Nick Northcott, Chrysalis Managing Partner talks about the importance of having good corporate and also research governance in place to provide assurance for investors. Nick highlights the gap in the research integrity space faced by the biotech and medtech industries in Australia and raises the need for independent and impartial research integrity services to manage complaints around research misconduct. Nick calls on the Boards of commercial biotechs and research organisations to take ownership and ensure they have the right research governance frameworks in place.

#biotech #medtech #researchgovernance #corporategovernance #researchintegrity #clinicaltrialsgovernance #clinicaltrials